((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
Overview
* Proteomics platform provider's Q3 revenue fell yr/yr
* Net loss narrowed to $13.7 mln, with operating expenses down 23% yr/yr
* Company cut 2026 revenue guidance, citing extended sales cycles from funding pressures
Outlook
* Seer lowers 2026 revenue guidance to $13.5 mln-$14.5 mln from $16 mln-$18 mln
* Company cites extended sales cycles due to pressure on academic and government funding
Result Drivers
* CUSTOMER ACTIVITY - Co said established customers made repeat consumables purchases and new pharmaceutical customers adopted its platform
* FUNDING PRESSURE - Co cited continued pressure on academic and government funding as extending sales cycles and delaying late-stage opportunities
* OPERATING COST REDUCTION - Co attributed lower operating expenses primarily to reduced employee compensation, including stock-based compensation
Company press release: ID:nGNX7HPcqW
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 $3.98
Revenue mln
Q3 Loss $0.25
Per
Share
Q3 Net $13.74
Loss mln
Q3 Gross 47.00%
Margin
Q3 Gross $1.88
Profit mln
Q3 $16.55
Operatin mln
g
Expenses
Analyst Coverage
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
* The average consensus recommendation for the office equipment peer group is "buy"
* Wall Street's median 12-month price target for Seer, Inc. is $4.00, about 138.1% above its November 9 closing price of $1.68
Reuters Recommended Reads
* Nov 9 - Canada's Xenon Pharmaceuticals posts smaller-than-expected Q3 net loss
* Nov 9 - Annexon Biosciences Q3 net loss narrows on lower R&D expenses, cash runway extends to 2028
* Nov 9 - Compass Therapeutics Q3 net loss widens on higher R&D expenses
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)